SAB Biotherapeutics- Unit (1 Ordinary share & 1/2 Wrt) Accounts Payable

As of the most recent data (June 2026), BCYPU shows a accounts payable of $3.9M. That compares with $2.6M in the prior-year period — up 47.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, BCYPU's accounts payable is now $3.9M (was $2.6M) — a 47.0% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether SAB Biotherapeutics- Unit (1 Ordinary share & 1/2 Wrt) is outperforming or lagging.

Tracking BCYPU's accounts payable over time shows whether SAB Biotherapeutics- Unit (1 Ordinary share & 1/2 Wrt) is scaling, shrinking, or reshaping that part of the business. The current reading is $3.9M That compares with $2.6M in the prior-year period — up 47.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this accounts payable page, Stockcircle has SAB Biotherapeutics- Unit (1 Ordinary share & 1/2 Wrt)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $3.9M) with ownership activity and broader fundamentals.